Stevanato Group S.p.A. (STVN)
- Previous Close
22.48 - Open
22.48 - Bid 22.43 x 800
- Ask 24.97 x 800
- Day's Range
22.39 - 24.24 - 52 Week Range
16.56 - 24.90 - Volume
625,398 - Avg. Volume
360,701 - Market Cap (intraday)
6.55B - Beta (5Y Monthly) 0.51
- PE Ratio (TTM)
50.00 - EPS (TTM)
0.48 - Earnings Date May 8, 2025
- Forward Dividend & Yield 0.06 (0.25%)
- Ex-Dividend Date Jun 5, 2025
- 1y Target Est
27.23
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass forming machines; and after-sales services, such as spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug product, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
www.stevanatogroup.com5,521
Full Time Employees
December 31
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: STVN
View More
Performance Overview: STVN
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: STVN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: STVN
View MoreValuation Measures
Market Cap
6.55B
Enterprise Value
6.92B
Trailing P/E
49.74
Forward P/E
38.91
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.25
Price/Book (mrq)
4.16
Enterprise Value/Revenue
5.59
Enterprise Value/EBITDA
24.89
Financial Highlights
Profitability and Income Statement
Profit Margin
11.18%
Return on Assets (ttm)
4.83%
Return on Equity (ttm)
9.16%
Revenue (ttm)
1.12B
Net Income Avi to Common (ttm)
125.78M
Diluted EPS (ttm)
0.48
Balance Sheet and Cash Flow
Total Cash (mrq)
91.13M
Total Debt/Equity (mrq)
27.86%
Levered Free Cash Flow (ttm)
-114.66M
Research Analysis: STVN
View MoreResearch Reports: STVN
View MoreDropping Coverage of Stevanato
Italy-based Stevanato Group is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato’s revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% in South America.
RatingPrice TargetStevanato's Sturdy Growth Shows No Signs of Slowing as Q2 Exceeds Forecasts; Shares Fairly Valued
Italy-based Stevanato Group is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato’s revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% in South America.
RatingPrice TargetStevanato Starts Year With Solid Q1, Sturdy Switching Costs Support Its Moat; Shares Undervalued
Italy-based Stevanato Group is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato’s revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% in South America.
RatingPrice TargetStevanato Starts Year With Solid Q1, Sturdy Switching Costs Support Its Moat; Shares Undervalued
Italy-based Stevanato Group is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato’s revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% in South America.
RatingPrice Target